Assembly of P2XRs
=================

Trimeric structure of P2XRs
---------------------------

Early electrophysiological measurements in bullfrog sensory neurons and single channel analysis of HEK cell-expressed P2X2Rs predicted that there are at least three ATP molecules needed to open a P2X channel (Bean, [@B14]; Ding and Sachs, [@B54]). Cross-linking studies and blue-native PAGE analysis of P2X1 and P2X3 receptors heterologously expressed in *Xenopus laevis* oocytes revealed the first biochemical evidence for a trimeric quaternary structure of P2XR channels (Nicke et al., [@B147]). This rather unexpected architecture was subsequently confirmed by atomic force microscopy (AFM) (Barrera et al., [@B12]), electron microscopy (EM), single particle analysis (Mio et al., [@B142]; Young et al., [@B232]) and finally the first crystal structure of a P2XR, the truncated zebrafish zP2X4R (Kawate et al., [@B104]), which constituted a major breakthrough in P2XR research. Unexpectedly, the crystal structure of the acid sensing ion channel (ASIC), a member of the ENaC/DEG (epithelial sodium channels/degenerin) superfamily, which shares the same topology and was published around the same time by the Gouaux group, also revealed a trimeric structure, although the two channels show no significant amino acid sequence relationships or similarities in the folding of their extracellular domains (Jasti et al., [@B91]; Gonzales et al., [@B76]; Kawate et al., [@B104]).

The overlapping expression patterns of various P2X subunits, the poor expression of functional P2X~5~ and P2X~6~ homomers in heterologous systems (see below), and the lack of correlation of the functional properties of heterologously expressed homomeric P2X3Rs with P2XRs found in dorsal root ganglions (Lewis et al., [@B130]), have early led to the assumption that P2XRs, like most ionic receptors, form heteromers. The existence of P2X heteromers is now firmly established but their specific composition and presence in native tissues remains in most cases enigmatic (see chapter Distribution of P2XR subunits). Likewise, their stoichiometry and determinants for subtype specific assembly are largely unclear. Biochemical and/or functional analysis of heterologously expressed P2X2/3 and P2X2/6 heteromers indicates a fixed stoichiometry of P2X2(3)~2~ (Jiang et al., [@B93]) and P2X(2)~2~6 (Hausmann et al., [@B85]), respectively. In contrast, a variable, expression-level-dependent stoichiometry for P2X2/6 heteromers was observed in atomic force imaging experiments (Barrera et al., [@B11]). Co-purification experiments with the P2X1/2 heteromer suggest a P2X1(2)~2~ stoichiometry (Aschrafi et al., [@B7]). So far, no evidence has been presented for the formation of complexes containing three different subunits.

Assembly domains and molecular structure of the P2XR
----------------------------------------------------

To investigate the role of the transmembrane domains (TMs) in subunit assembly, Torres and colleagues performed co-precipitation studies in HEK cells and found that the association of P2X2 subunits with either itself or P2X3 subunits was prevented if TM2 and the preceding 25 amino acids were deleted (Torres et al., [@B199]). To confirm the hypothesis that TM2 rather than the extracellular domain is critical for subunit assembly, these investigators made use of the finding that P2X6 subunits were able to co-immunoprecipitate with P2X1 but not P2X3 subunits (Torres et al., [@B198]). Using chimeras in which the extracellular loops between P2X1 and P2X3 subunits were swapped they could demonstrate that only the chimera containing the P2X1 TMs was able to co-immunoprecipitate the P2X6 subunit. In a subsequent study on the hP2X5R splice variant that lacks the C-terminal end of the ectodomain and the outer half of the TM2, it was shown that tethering of the C-terminal end of the ectodomain by membrane insertion of TM2 and the intramembrane positioning of D355 are critical for homotrimeric assembly (Duckwitz et al., [@B61]). It was concluded that membrane insertion of TM2 restricts the conformational mobility of the ectodomain and thus enables correct positioning of assembly recognition sites located in the ectodomain, while D355 assists in the hydrogen bond-driven transmembrane helix-helix associations. In the zP2X4R crystal structure, however, it is seen that inter-subunit contacts are largely formed between the ectodomains (Kawate et al., [@B104]). The homotrimeric zP2X4R resembles a chalice, with the large extracellular domain raising \~70 Å above the membrane plane and the six TM helices forming the shape of an hourglass. The single zP2X4 subunit structure has been compared with the shape of a jumping dolphin, in which the two TM helices and the largest part of the extracellular region form the fluke and the upper body, respectively. Attached to the large body domain, a flexible head domain, a dorsal fin, and right and left flippers have been defined. The body domain appears structurally rigid due to extensive β-sheet contacts within a β-sandwich motif. Three interfaces with close contact between adjacent subunits were defined; upper-body-to-upper-body, head-to-body and left-flipper-to-dorsal-fin. Thus, the contacts between neighboring subunits are restricted to the upper ectodomains. The lack of significant contacts between the lower bodies of the extracellular domains enables significant movements in these domains during ATP-induced channel opening (Kawate et al., [@B104]; Hattori and Gouaux, [@B84]). It was suggested that the more conserved body domains constitute a common assembly interface in all P2XRs, while the less conserved dorsal fin, head, and left flipper domains guide the subunit-specific assembly by the head-to-body and left-flipper-to-dorsal-fin contacts (Kawate et al., [@B104]). The low conservation of the latter domains has an important consequence: While homotrimeric P2XRs contain three identical subunit-subunit interfaces, heteromeric P2XRs form always three significantly different interfaces between the "head-to-tail" arranged subunits (see also "Specific characteristics of the ATP sites in heteromeric P2XRs").

The intersubunit ATP-binding site
---------------------------------

Most of the conserved amino-acid residues involved in the interaction with ATP have been identified in mutagenesis-based studies (Ennion et al., [@B66]; Jiang et al., [@B94]; Roberts and Evans, [@B168]; Yan et al., [@B231]; Roberts and Evans, [@B169]; Wilkinson et al., [@B218]; Young et al., [@B233]; Fischer et al., [@B70]; Zemkova et al., [@B235]; Roberts et al., [@B167]; Donnelly-Roberts et al., [@B57]; Evans, [@B67]; Roberts et al., [@B170]; Browne et al., [@B27]; Evans, [@B68]; Bodnar et al., [@B20]). Based on disulfide cross-linking experiments, in which some of these residues were substituted by cysteine residues, it was concluded that the agonist binding site is located at the interface between two neighboring subunits (Marquez-Klaka et al., [@B138]). Crystallization of the zP2X4R showed that these residues surround a large intersubunit cavity, which was proposed to constitute the ATP binding site. This cavity is formed between two complementary half-shells contributed by the adjacent subunits A and B. When viewed from the side (i.e., in parallel to the membrane plane), the upper left and the lower right boundaries of each ATP-binding site are constituted by the upper body and the left flipper of subunit A and the lower body and dorsal fin of subunit B, respectively (Kawate et al., [@B104]). By labeling of engineered cysteines with thiol-reactive ATP-analogs (Jiang et al., [@B95]) and by voltage-clamp fluorometry studies (Lörinczi et al., [@B135]), it was confirmed that this cavity constitutes the ATP binding site and that the flexible head domain of subunit A that projects over the binding site moves substantially during ligand binding and/or channel gating (Hattori and Gouaux, [@B84]; Jiang et al., [@B97]; Lörinczi et al., [@B135]). The zP2X4 structure provided a basis for rational mutant design, *in silico* docking, and molecular dynamics simulations which were crucial to identify the three lateral ion-access-pathways, and to improve our understanding of the molecular mechanisms of ligand binding and channel gating (Jiang et al., [@B96]; Rokic et al., [@B172]; Allsopp et al., [@B4]; Bodnar et al., [@B20]; Jiang et al., [@B95]; Kawate et al., [@B105]; Samways et al., [@B177]; Wolf et al., [@B223]; Du et al., [@B59]; El-Ajouz et al., [@B65]; Jiang et al., [@B97]; Lörinczi et al., [@B135]; Roberts et al., [@B166]; Hausmann et al., [@B86]). However, docking of ATP proved difficult due to the spatial diversity of the ATP-binding pockets of different P2X subtypes, the high flexibility of the critical lysine residues, and a multitude of possible binding-modes within the relatively large (compared to the ATP molecule) binding pocket. The precise mode of ATP-binding was only determined by crystallization of an ATP-bound zP2X4R (Hattori and Gouaux, [@B84]). The phosphate chain and the adenine ring of the ATP molecule are folded in an U-shaped configuration within the ATP-binding pocket. The phosphate oxygens of ATP are coordinated by the side chains of K70 and K72 within the lower body of subunit B and N296, R298, and K316 within the upper body of subunit A (zP2X4 numbering). In agreement with labeling experiments at the P2X2R using a thiol-reactive ATP-analog (Jiang et al., [@B95]), the adenine base of ATP is making hydrophobic interactions with L191 of the lower body and I232 of the dorsal fin (subunit B). It is further stabilized by hydrogen bonds with the side chain of T189 and the backbone of K70, both located within the lower body of subunit B. The ribose moiety is facing the solution (Lörinczi et al., [@B135]) and recognized solely by hydrophobic interactions with L217 within the dorsal fin of subunit B (Hattori and Gouaux, [@B84]).

Specific characteristics of the ATP-binding sites in heteromeric P2XRs
----------------------------------------------------------------------

Under the condition of similar conformations of the subunits and their uniform arrangement (Kawate et al., [@B104]; Hattori and Gouaux, [@B84]), three equivalent intersubunit ATP-binding sites can be assumed in one homomeric P2XR. Based on the zP2X4 structure, homology models of the ATP-binding sites of homomeric P2X1, P2X2, P2X3, P2X4, and P2X7 receptors have been generated so far (Keceli and Kubo, [@B106]; Roger et al., [@B171]; Allsopp et al., [@B4]; Bodnar et al., [@B20]; Jiang et al., [@B95]; Wolf et al., [@B223]; El-Ajouz et al., [@B65]; Jiang et al., [@B97]; Lörinczi et al., [@B135]; Roberts et al., [@B166]; Schwarz et al., [@B178]; Hausmann et al., [@B86]). As outlined above, three significantly different intersubunit binding sites are formed in the case of heteromeric P2X assemblies: one between two identical subunits and two at the heteromeric interfaces A/B and B/A. The structural differences of the latter two are mainly due to structural differences in the upper bodies and left flippers as exemplarily shown for P2X2 and P2X3 subunits (Figure [1](#F1){ref-type="fig"}) and lead to different interfaces and volumes of the hydrophilic cavities. In addition, the overlapping head domains differ significantly in their backbone conformation and side chain orientation. These domains are characterized by a highly conserved pattern of three disulfide bridges that constrain the rather non-conserved sequences between the cysteine residues in loops of different length and structure. Although these domains do not directly contribute to ATP binding, they appear to be important for channel gating and might have crucial influence on antagonist selectivities (Wolf et al., [@B223]; El-Ajouz et al., [@B65]; Hattori and Gouaux, [@B84]; Jiang et al., [@B97]; Lörinczi et al., [@B135]; Roberts et al., [@B166]). The side chains of residues responsible for the coordination of ATP, e.g., as illustrated for selected basic residues in Figure [1](#F1){ref-type="fig"}, are in different spatial orientation and in unequal distances relative to each other. Evidence for varying distances and/or orientation of residues critical for ATP binding was also obtained in cysteine cross-linking experiments at P2X1/P2X2 interfaces in the respective heteromer (Marquez-Klaka et al., [@B139]). Here, co-expression of K68C-P2X1 and F289C-P2X2 subunits resulted in spontaneous intersubunit cross-linking, while co-expression of F291C-P2X1 and K69C-P2X2 subunits did not produce significant amounts of SDS-resistant dimers. As a consequence of the spatial orientations, unequal binding sites are formed where ligands likely adopt substantially different binding modes and consequently different binding affinities and specificities. This is reflected in distinct pharmacological characteristics of heteromeric and homomeric P2XRs (Gever et al., [@B74]; Jarvis and Khakh, [@B90]; Coddou et al., [@B43]) and may open the possibility for the development of ligands that are able to specifically block heteromeric P2XRs. However, so far it is not known, if a heteromeric P2XR can be blocked by specific targeting of one of the two heteromeric ligand binding sites or how many binding sites have to be occupied by antagonists to inhibit the channel.

![**Homology model of the closed state of the human P2X2/3R. (A)** A side view of the heterotrimeric hP2X2(3)~2~R in which both heteromeric interfaces are visible is shown in the middle. The P2X2 subunit is colored in cyan and the two P2X3 subunits are colored in orange and pink. Selected basic residues important for ATP binding are shown as spheres within the two intersubunit ATP-binding sites. For clarity, the same residues are shown as sticks in a close-up view with depiction of the distances between their side chains. **(B)** Frontal close-up views of the two heteromeric ATP-binding sites with a partial transparent surface to indicate the orientation of the residues. The coloring of the subunits is the same as in **(A)**. Differences in the three-dimensional structures and volumes of the hydrophilic cavities are clearly seen. **(C)** Surface representations of the same view as in **(B)** with gradual depiction of hydrophobic (green) or hydrophilic (pink) areas/residues. Neutral areas are shown gradually white. The hP2X2/3R homology model was generated and visualized by the molecular modeling program MOE2012.10 (Molecular Operating Environment 2012, CCG, Montreal, Canada) using the apo zP2X4 crystal structure (PDB entry 3H9V; (Kawate et al., [@B104]) as a template as previously described (Wolf et al., [@B223]; Hausmann et al., [@B86]).](fncel-07-00250-g0001){#F1}

Cooperativity of ATP binding in P2XRs
-------------------------------------

Binding of agonist is supposed to induce channel opening by a closing movement of the head domain that is further propagated to the TM domains (Hattori and Gouaux, [@B84]; Jiang et al., [@B97]; Lörinczi et al., [@B135]). Dose response curves for ATP yield generally Hill-slopes greater than one (Bean, [@B15]; Brake et al., [@B23]) indicating that more than one agonist molecule binds before channel opening occurs. However, analyses of dose response curves are deceptively complex (Colquhoun, [@B45]) and the Hill-slope can only serve as a rough estimate of the minimum number of binding sites. The reduced Hill coefficients observed for agonist dose response curves at heteromeric P2XRs (Torres et al., [@B200]; Haines et al., [@B81]; Surprenant et al., [@B195]; Jiang et al., [@B93]) might suggest that the heteromers require fewer agonist molecules for opening but could also be explained by factors like altered cooperativity or desensitization. From electrophysiological analysis and mathematical modeling of the activation and deactivation kinetics of the P2X2, P2X3, and P2X7 receptors it was concluded that two ATP molecules are sufficient to open the channels while occupation of three binding sites enables dilation of the pore in P2X2 and P2X7 subtypes (Karoly et al., [@B101]; Yan et al., [@B229]; Khadra et al., [@B109]). As detailed below, co-expression of wt (wild type) P2X6 subunits rescued ATP-elicited currents of P2X2 subunits with defective ATP-binding sites. Since receptors with one non-functional ATP-binding site can be activated, this supports the model in which binding of two ATP molecules is sufficient for channel gating (Wilkinson et al., [@B218]; Hausmann et al., [@B85]). Similar studies with concatenated subunits indicate that this is also valid for homomeric P2X2Rs (Stelmashenko et al., [@B190]). In contrast, photoaffinity labeling data at a homomeric non-desensitizing P2X2/1 chimera are better described by a model in which three BzATP molecules must bind to open the channel (Bhargava et al., [@B16]). In case that binding of two ATP molecules is sufficient to induce channel opening, ATP would need to bind and induce closure of the head domain in at least two of the three distinct ATP-binding sites in heteromeric P2XRs. For antagonists, the situation is likely different. Like in other ligand-gated ion channels, orthosteric antagonists of P2XR are generally larger molecules and supposed to block the closing movement or even induce an opening of the ATP-binding pocket (Du et al., [@B60]), thereby preventing the initial gating step. Provided that simultaneous symmetric conformational changes of the three subunits should be favored, it might depend on the size of antagonist if targeting of one ATP binding sites is sufficient to prevent the ATP-induced gating of the whole trimeric channel. In case of the muscle-type nAChR for example, it appears, that occupation of only one agonist binding site by specific peptide antagonists is sufficient to inhibit channel opening, although it has to be considered that this channel has only two agonist binding sites (Groebe et al., [@B77]).

Properties of heterologously expressed P2XRs
============================================

Homomeric expression
--------------------

When heterologously expressed, most mammalian P2X subunits readily form homotrimeric complexes with functional and pharmacological properties described below. For P2X5Rs species-specific differences in expression efficiency and functional properties such as ion permeability were observed (Collo et al., [@B44]; Garcia-Guzman et al., [@B73]; Cox et al., [@B50]; Jensik et al., [@B92]; Ruppelt et al., [@B175]; Diaz-Hernandez et al., [@B53]; Wildman et al., [@B217]). This subunit occurs in humans predominantly as a non-functional splice variant (Le et al., [@B126]; Bo et al., [@B18]; Duckwitz et al., [@B61]) and expression of the mouse and rat isoforms is inefficient (Collo et al., [@B44]; Cox et al., [@B50]; Wildman et al., [@B217]). For P2X6Rs, heteromerization with other subunits appears to be obligatory for correct folding and trimeric assembly (see below) (Collo et al., [@B44]; Soto et al., [@B187]; Nawa et al., [@B145]; King et al., [@B114]; Aschrafi et al., [@B7]; Barrera et al., [@B12]).

P2XRs are generally classified in rapidly desensitizing (P2X1 and P2X3), and slowly or non-desensitizing (P2X2, P2X4, P2X5, and P2X7) receptors although desensitization properties can change under cell-free conditions (Ding and Sachs, [@B55]). For P2X2, P2X4, and P2X7 receptors, additional permeability states have been described (Khakh et al., [@B111]; Virginio et al., [@B207],[@B208]; Khadra et al., [@B109], [@B108]), for details see (Kaczmarek-Hajek et al., [@B100]), which are little understood on the molecular level.

Agonist pharmacology of homomeric P2XRs
---------------------------------------

As a recent and detailed review of P2XR pharmacology is available (Coddou et al., [@B43]), the following paragraphs summarize only some of the key functional properties of homomeric P2XRs with a focus on those characteristics that have been used to differentiate homomeric and heteromeric P2XRs.

The EC~50~ values for ATP range from submicromolar concentrations for P2X1, P2X3, and P2X5 to low micromolar concentrations for P2X2 and P2X4 receptors. At the P2X7R, EC~50~ values for ATP range from about 0.1 to 1 mM for the rat and mouse isoforms, respectively. BzATP is at least one order of magnitude more potent at this receptor (Rassendren et al., [@B161]) but has also considerable activity at other P2X isoforms (Anderson and Nedergaard, [@B5]). Agonist potency at P2X7Rs decreases if Ca^2+^ or Mg^2+^ are present in the recording solution. Ca^2+^ decreases the potency of orthosteric agonists independently of the free agonist concentration, thus acting as an allosteric inhibitor (Yan et al., [@B230]). In the case of Mg^2+^, the inhibition seems to be due to both an inhibitory Mg^2+^ binding site and a lower or absent agonist activity of Mg^2+^-bound ATP at the P2X7R (Virginio et al., [@B206]; Klapperstück et al., [@B117]; Acuna-Castillo et al., [@B1]). Differences in the sensitivity to free ATP and Mg^2+^-bound ATP were also reported for P2X2 and P2X4 receptors but not seen with P2X1, P2X2/3, and P2X3 receptors (Li et al., [@B132]).

All P2XR agonists known so far are nucleotide analogs. ATPγS and αβ-meATP are metabolically more stable and widely used to investigate ATP-gated channels in native tissues. In addition, 2-MeSATP, diadenosine polyphosphates, and other nucleoside triphosphates are used as P2X agonists. Interestingly, fast desensitization and slow recovery from desensitization of P2X1R and P2X3R seems to be associated with the formation of high-affinity binding sites for ATP, αβ-meATP, and the antagonist trinitrophenyl-ATP (TNP-ATP). At homomeric P2X2Rs, αβ-meATP is an agonist with very low potency (EC~50~ \>100 μM), while homomeric P2X4Rs are activated in a species-dependent manner with EC~50~ values ranging from 5 to 100 μM. P2X7Rs are not readily activated by αβ-meATP (EC~50~ \>\> 100 μM). In heteromeric assemblies, P2X1, P2X3, P2X5, or P2X6 subunits appear to confer αβ-meATP sensitivity. In contrast, the diadenosine tetraphosphate Ap~4~A, is a full and potent agonist at the homomeric P2X2R (Pintor et al., [@B156]; Wildman et al., [@B215]), but is inactive at the heteromeric P2X2/6R (King et al., [@B114]).

Antagonist pharmacology of homomeric P2XRs
------------------------------------------

The large polysulfonated naphtylurea suramin and the pyridoxalphosphate derivative PPADS are among the earliest and still most widely used P2XR antagonists. Suramin also inhibits other purinergic receptors and G-proteins and more specific analogs ("NF compounds") have been developed. Of these, NF449 is highly selective for P2X1Rs and NF770 is moderately selective for P2X2Rs. PPADS is a more specific inhibitor for P2 receptors but acts in a non-competitive way. More potent analogs ("MRS compounds") with certain selectivity for P2X1 (MRS2220), P2X1 and P2X3 (MRS2257), and P2X1, P2X3, and P2X7 (MRS2159) have been developed (Coddou et al., [@B43]).

The nucleotide analog TNP-ATP is a competitive antagonist with nanomolar affinity for recombinant P2X1, P2X3, and P2X2/3 receptors, and micromolar affinity for recombinant P2X2 and P2X4 receptors (King et al., [@B115]; Virginio et al., [@B209]). Another nucleotide-based antagonist diinosine pentaphosphate (IP~5~I) showed improved stability in native tissues and is a potent and selective P2X1R antagonist (King et al., [@B113]). Oxidized ATP is used as an irreversible P2X7 antagonist but requires extensive pre-incubation. New types of mostly non-nucleotidic and subtype-specific antagonist have been developed during the last two decades. These efforts focused mainly on the P2X3 and P2X7 subtypes that appeared to be the most relevant drug targets. Among others, the P2X3 and P2X2/3-selective antagonists RO-51, RO-3, TC-P262, AF353 (RO-4), A-317491 and the P2X7-selective antagonists A-438079, A-740003, A-804598, A-839977, AZ 11645373, AZ 10606120 are commercially available. In particular for P2X7Rs, however, species specificity has to be considered. The commonly used inhibitors KN-62 and BBG for example, are selective for human and rat P2X7 isoforms, respectively (Donnelly-Roberts et al., [@B57]).

At the P2X4R, which has been difficult to target, 5-BDBD has been shown to be a comparably potent blocker (IC~50~ \~ 0.5 μM) (Donnelly-Roberts et al., [@B58]) and very recently, PSB-12054 was introduced as hP2X4R antagonist with submicromolar potency (IC~50~ \~ 0.2 μM) (Hernandez-Olmos et al., [@B87]). In addition, more specific P2X2-antagonists, the anthrachinone derivatives PSB-10211 and PSB-1011, were introduced (Baqi et al., [@B10]).

Allosteric modulators of P2XRs
------------------------------

Acidification enhances responses of agonists and suramin at the rat P2X2R (King et al., [@B115]). Likewise, P2X2/3 (Stoop et al., [@B192]) and, with a distinct pattern, P2X2/6 (King et al., [@B114]) and P2X1/2 (Brown et al., [@B26]) receptors are modulated by protons (see below). Mutation of H319 to alanine removed the potentiating effect of acidification on rat P2X2Rs (Clyne et al., [@B37]). Its characteristic modulation by protons can help to distinguish P2X2Rs since all other homomeric P2XRs are inhibited by acidification \[for details see (Coddou et al., [@B43])\].

Mg^2+^ was recently shown to directly inhibit P2X1, P2X3, and P2X7 receptors, while P2X2 and P2X2/3 receptor responses were insensitive or less sensitive to Mg^2+^ when activated by supermaximal concentrations of free ATP (Li et al., [@B132]).

The trace metals Zn^2+^ and Cu^2+^ allosterically modulate P2XRs in complex subtype- and species-specific ways and via non-conserved binding sites \[for details see (Coddou et al., [@B42])\]. In summary, Zn^2+^ inhibits P2X1 and P2X7 receptor currents and modulates P2X2, P2X3, P2X4, and P2X5R currents in a biphasic way, i.e., it potentiates at low concentrations and inhibits at high concentrations. The Zn^2+^ binding site of the rat P2X2R has been localized at the interface between adjacent subunits (Nagaya et al., [@B144]). Like zinc, copper modulates the rat P2X2R in a biphasic way, while the human P2X2R and the P2X7R are only inhibited by zinc and copper (Tittle and Hume, [@B197]; Coddou et al., [@B42]). A peculiarity of the P2X4R is that it is differentially modulated by Zn^2+^ and Cu^2+^. While Zn^2+^ and Cu^2+^ both coordinate at the inhibitory allosteric site, Zn^2+^ can additionally bind to a positive allosteric site explaining the different modulatory effects of zinc and copper at the P2X4R (Coddou et al., [@B41], [@B40], [@B42]).

The antiparasitic agent ivermectin (IVM) has agonist properties at invertebrate glutamate receptors (GluRs) and is also pharmacologically active at a number of other ligand-gated ion channels. At homomeric and heteromeric P2X4Rs it is an allosteric modulator (Khakh et al., [@B111]; Priel and Silberberg, [@B157]). In the absence of efficient P2X4R inhibitors, it has been widely used as a tool to dissect P2X4 subunit containing receptors. However, more recent studies show that IVM can also species-specifically potentiate P2X7R current amplitudes (Casas-Pruneda et al., [@B35]; Surprenant and North, [@B194]; Nörenberg et al., [@B149]).

Pharmacology of heteromeric receptors
-------------------------------------

In most functionally characterized heteromers (see below) the kinetic and ligand-binding properties of the constituting subunits are combined and the slowly desensitizing subunit generally dominates the kinetic, while the subunit with higher affinity for agonist and/or antagonist appears to increase the sensitivity of the heteromer for the respective ligand.

In agreement with this, the P2X2/3 heteromer appears to adopt largely the pharmacological profile (agonist potency, TNP-ATP sensitivity) of the P2X3 subunit, which is present twofold within the complex (Jiang et al., [@B93]). Although their stoichiometry is not known, the P2X1/4R and the P2X1/5R also show a pharmacological profile more similar to the P2X1R and kinetic properties that resemble the P2X4R or P2X5R, respectively (Coddou et al., [@B43]). The often slightly lower potency of agonists at the heteromers is too subtle for a true discrimination from the P2X1 or P2X3 homomer and most likely reflects a lower affinity for ATP at the heteromeric ATP-binding sites. In case of the heteromeric P2X2/6 or P2X4/6 receptors the pharmacological properties are similar to that of the P2X2R or P2X4R, respectively (Coddou et al., [@B43]). For the P2X2/6R a stoichiometry of two P2X2 and one P2X6 subunits was suggested (Hausmann et al., [@B85]). The heteromeric P2X1/2R shows a kinetic and pharmacological profile that resembles the P2X1R, although a P2X1(2)~2~ stoichiometry has been suggested (Aschrafi et al., [@B7]). However, it adopted the pH sensitivity from the P2X2 subtype (Brown et al., [@B26]). The H^+^ and Zn^2+^ sensitivity of the P2X2 subtype are also conferred to the P2X2/3 and P2X2/6 heteromers (Li et al., [@B131]; Stoop et al., [@B192]; King et al., [@B114]).

There are a few compounds that appear to be able to discriminate between homomeric and heteromeric P2XRs. The photoreactive \[γ−^32^P\]8-Azido-ATP is an effective agonist at homomeric P2X3Rs but not at heteromeric P2X2/3Rs. It also efficiently labeled homomeric P2X3Rs, but was inefficient at homomeric P2X2Rs and heteromeric P2X2/3Rs (Koshimizu et al., [@B119]). Likewise, Ip~5~I was shown to inhibit α,βme-ATP-induced responses of homomeric P2X1 and P2X3 receptors with low micromolar potency, but is virtually inactive at the heteromeric P2X2/3R and the homomeric P2X2R (King et al., [@B113]; Dunn et al., [@B62]). Also RO-85, an orally bioavailable drug-like P2X3R antagonist, is selective for the P2X3R over the P2X2/3R and other P2XR subtypes (Brotherton-Pleiss et al., [@B25]). Interestingly, all these substances appear to lose their affinity at the heteromeric receptor despite the fact that at least one P2X3-P2X3 interface is preserved in the heteromer. Possible explanations for this discrepancy would be, that the P2X3-P2X3 interface is markedly altered by inclusion of the single P2X2 subunit in the complex and/or that occupation of one interface is insufficient and more than one ligand has to bind to produce an efficient channel block. So far, no compound has been identified, that is selective for any of the heteromeric receptors. Thus, it remains questionable, if the two requirements for selective heteromer targeting (1) selective binding to one (or both) heteromeric interfaces and (2) efficient blockade of the whole receptor by occupation of one (or both) heteromeric interface(s) can be fulfilled. In case of small antagonists, the specific recognition area (contributed by both subunits) might be too small and the critical lysine residues too flexible to allow high selectivity. Also, the small ligand volume and the comparably few interactions with both subunits might not provide sufficient steric hindrance to allosterically block the gating movements in all three subunits.

In this regard, it is also important to consider that P2XRs differ substantially from other ligand-gated ion channels in having three intersubunit ion access pathways that widen during channel opening (Kawate et al., [@B105]; Samways et al., [@B177]; Hattori and Gouaux, [@B84]; Roberts et al., [@B166]). In combination with the high flexibility of the lower ectodomains and their linkers to the TMs, this might enable P2XRs to tolerate or compensate also more or less pronounced antagonist induced conformational changes before a complete channel block occurs.

Distribution of P2XR subunits
=============================

Although transcripts for more than one P2X subunit are found in most cell types (Table [1](#T1){ref-type="table"}), there is good evidence (in particular from studies on knockout mice) for homomeric P2X1, P2X2, P2X3, P2X4, and P2X7 receptors in at least some native tissues (e.g., Cockayne et al., [@B38]; Finger et al., [@B69]; Sim et al., [@B182]; Nicke, [@B146]). However, properties of heterologously expressed homomeric P2XRs more often do not match with those observed in native tissues. In addition to the heteromers described below and yet unidentified combinations of two or three different P2X subunits, splice variants and interacting proteins most likely contribute to the diversity of P2XR signaling.

###### 

**Summary of the distribution of P2XR subunits in selected mammalian cell types**.

  **Cell line/type**                                                                                                                                                                                                                                                **Identified transcripts**   **Identified protein**                **Functional data similar to**                                                                                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------------------- -------------------------------- ----- ----- ----- ----- ------------------------------------- ----- ------------------------------------- ----- ----- ----- ----- ----------------------------------------------------------------------------
  T-cells: Jurkat cell line^(^[^1^](#TN1){ref-type="table-fn"}^)^                                                                                                                                                                                                   (+)                                                                                                 \+    \+          (+)   \+                                                                                \+                \+    Ca^2+^ imaging, siRNA: P2X1, P2X4, P2X7
  T-cells: human primary CD4+^(^[^1^](#TN1){ref-type="table-fn"}^)^                                                                                                                                                                                                 (+)                                                                                                 \+    \+          \+    \+                                                                                \+                      Pharmacological inhibition, Ca^2+^ imaging: P2X1, P2X4
  Mast cells: LAD2 and human lung mast cells^(^[^2^](#TN2){ref-type="table-fn"}^)^                                                                                                                                                                                  \+                                                                                                  \+          (+)   \+                                                                                                              Patch clamp: P2X1, P2X4, P2X7
  Freshly isolated mouse peritoneal macrophages^([3](#TN3){ref-type="table-fn"},\ [4](#TN4){ref-type="table-fn"},\ [46](#TN46){ref-type="table-fn"})^                                                                                                               (+)                                                                                                 \+                \+    \+                                                                                \+                      KO mouse: P2X1, P2X4
  J774 cells^(^[^5^](#TN5){ref-type="table-fn"}^)^                                                                                                                                                                                                                                                                                     \+                               \+    (+)   \+    \+                                          \+                                          \+                \+    Ca^2+^ imaging, patch clamp: P2X4, P2X7
  Mouse spleen macrophages^(^[^5^](#TN5){ref-type="table-fn"}^)^                                                                                                                                                                                                                                                                       \+                               \+    \+    \+    \+    (+)                                   (+)   \+                                    \+    \+    \+    \+    
  Human B lymphocytes^([6](#TN6){ref-type="table-fn"},\ [7](#TN7){ref-type="table-fn"})^                                                                                                                                                                            \+                                                                                                  \+                \+    \+                                    \+                                          \+                \+    
  HeLa cells^(^[^8^](#TN8){ref-type="table-fn"}^)^                                                                                                                                                                                                                                                                                     (+)                              \+    \+    \+    \+                                                                                                        \+    Ca^2+^ imaging, changes in ATP-induced apoptosis: P2X7
  Myocytes from renal artery^(^[^9^](#TN9){ref-type="table-fn"}^)^                                                                                                                                                                                                  \+                                                                                                  \+                                                                                                                                Patch clamp: P2X1, P2X1/4
  Endothelial cells^([10](#TN10){ref-type="table-fn"},\ [11](#TN11){ref-type="table-fn"},\ [12](#TN12){ref-type="table-fn"})^                                                                                                                                       \+                                                                                                  \+    (+)         \+                                                                                      \+                \+    Ca^2+^ imaging: P2X4; KO mouse: P2X4, P2X1; patch-clamp: P2X7
  Dorsal root ganglia (DRG) neurons^([13](#TN13){ref-type="table-fn"},\ [14](#TN14){ref-type="table-fn"},\ [15](#TN15){ref-type="table-fn"},\ [16](#TN16){ref-type="table-fn"},\ [17](#TN17){ref-type="table-fn"})^                                                                              \+ [^a^](#TNa){ref-type="table-fn"}   \+                               \+                                                            \+    \+                                          \+                Patch clamp: P2X3, P2X2/3; KO mouse: P2X3, P2X2, P2X2/3
  Nodose ganglia neurons^([13](#TN13){ref-type="table-fn"},\ [15](#TN15){ref-type="table-fn"})^                                                                                                                                                                                                  \+                                    \+                               \+                                                            \+    \+                                                            Patch clamp, KO mouse: P2X2, P2X2/3
  Superior cervical ganglion (SCG) neurons^([13](#TN13){ref-type="table-fn"},\ [18](#TN18){ref-type="table-fn"},\ [19](#TN19){ref-type="table-fn"})^                                                                                                                (+)                          \+                                    \+                               \+    \+    \+    (+)   \+                                    \+    (+)                                   \+          \+          Patch clamp, Ca^2+^ imaging: predominantly P2X2; KO mouse: P2X1
  Urinary bladder afferent neurons^([15](#TN15){ref-type="table-fn"},\ [20](#TN20){ref-type="table-fn"},\ [21](#TN21){ref-type="table-fn"},\ [22](#TN22){ref-type="table-fn"})^                                                                                                                                                                                                                                                       \+    \+                                                            Bladder function, patch clamp: P2X3, P2X2/3; KO mouse: P2X2, P2X3, P2X2/3
  P19 cells^([23](#TN23){ref-type="table-fn"},\ [24](#TN24){ref-type="table-fn"},\ [25](#TN25){ref-type="table-fn"},\ [26](#TN26){ref-type="table-fn"})^                                                                                                                                                                                                                                                                                                                                                  Ca^2+^ imaging: P2X2, P2X2/6, P2X4; RNAi: P2X2, P2X7
  Undifferentiated                                                                                                                                                                                                                                                                               (+)                                   \+                               \+    \+    (+)   (+)                                         (+)   (+)                                   \+          (+)         
  Differentiated to progenitors                                                                                                                                                                                                                                     (+)                          \+                                    (+)                              (+)   \+    \+    \+    (+)                                   \+    (+)                                   (+)         \+    (+)   
  Neuronally differentiated neural progenitors^(^[^27^](#TN27){ref-type="table-fn"}^)^                                                                                                                                                                                                           \+                                    (+)                              (+)   (+)   \+                                                                                                                    
  Astrocytes^([28](#TN28){ref-type="table-fn"},\ [29](#TN29){ref-type="table-fn"},\ [30](#TN30){ref-type="table-fn"},\ [31](#TN31){ref-type="table-fn"})^                                                                                                           \+                           (+)                                   \+                               \+    \+    \+    \+    \+                                    \+    \+                                    \+          \+    \+    Patch clamp: P2X1/5; YO-PRO uptake, RNAi: P2X7
  Microglia^([32](#TN32){ref-type="table-fn"},\ [33](#TN33){ref-type="table-fn"},\ [34](#TN34){ref-type="table-fn"},\ [34](#TN34){ref-type="table-fn"},\ [35](#TN35){ref-type="table-fn"},\ [36](#TN36){ref-type="table-fn"},\ [46](#TN46){ref-type="table-fn"})^                                                                                                                                                                                                                                         Nerve injury, KO mouse: P2X4; patch clamp: P2X4, P2X7; YO-PRO uptake: P2X7
  Freshly isolated                                                                                                                                                                                                                                                  (+)                                                                                                 \+                \+                                                                                                              
  Primary culture                                                                                                                                                                                                                                                                                                                                                                                                                                                                 \+                \+    
  BV-2 cells                                                                                                                                                                                                                                                                                                                                                            \+          \+    \+                                                                                      \+                      
  C8-B4 cells                                                                                                                                                                                                                                                                                                                          (+)                              \+                \+                                                                                      \+                \+    
  Oligodendrocytes^(^[^38^](#TN38){ref-type="table-fn"}^)^                                                                                                                                                                                                                                                                                                                                                                                                                                          \+    Ca^2+^ imaging: P2X7
  Oligodendrocytes (progenitors)^(^[^37^](#TN37){ref-type="table-fn"}^)^                                                                                                                                                                                                                                                                                                                        \+                                    \+    \+                                    \+                \+    Ca^2+^ imaging, patch clamp: P2X7
  Human salivary gland epithelial (HSG) cells^(^[^39^](#TN39){ref-type="table-fn"}^)^                                                                                                                                                                                                                                                                                                           \+                                    \+    \+                                    \+    \+    \+          
  Human embryonic kidney (Hek) 293 cells^(^[^39^](#TN39){ref-type="table-fn"}^)^                                                                                                                                                                                                                                                                                                                                                                                                                          
  Normal conditions                                                                                                                                                                                                                                                                                                                                                                                                                                                               (+)   (+)               
  Grown past confluence                                                                                                                                                                                                                                                                                                                                                                         \+                                          \+                                    \+    \+    \+          
  Vascular smooth muscle cells^([40](#TN40){ref-type="table-fn"},\ [41](#TN41){ref-type="table-fn"},\ [42](#TN42){ref-type="table-fn"})^                                                                                                                            \+                           \+                                                                     \+                      \+ [^b^](#TNb){ref-type="table-fn"}         \+ [^c^](#TNc){ref-type="table-fn"}   \+    \+          \+    Patch clamp: P2X1[^b^](#TNb){ref-type="table-fn"}
  Non-cystic fibrosis epithelial cells (16HBE14o^−^)^(^[^43^](#TN43){ref-type="table-fn"}^)^                                                                                                                                                                                                                                                                                        \+                                                                                                  \+    \+          
  Cystic fibrosis cells (IB3-1)^(^[^43^](#TN43){ref-type="table-fn"}^)^                                                                                                                                                                                                                                                                                                 \+    \+    \+                                                                                            \+    \+    \+          RNAi, Ca^2+^ imaging: P2X4, P2X6
  Adrenal gland pheochromocytoma (PC12) cells^([44](#TN44){ref-type="table-fn"},\ [45](#TN45){ref-type="table-fn"})^                                                                                                                                                                                                                                                                                                                                                                                      Patch clamp, Ca^2+^ imaging: P2X2
  Undifferentiated                                                                                                                                                                                                                                                                               \+                                                                                                                                   \+                                                                  
  NGF-differentiated                                                                                                                                                                                                                                                \+                           \+                                    \+                               \+    \+    \+    \+    \+                                    \+    \+                                    \+    \+    \+    \+    

Except primates,

except septal vessels,

except cerebral vessels.

References in table:

Woehrle et al., [@B221];

Wareham et al., [@B212];

Sim et al., [@B182];

Ulmann et al., [@B205];

Coutinho-Silva et al., [@B49];

Sluyter et al., [@B184];

Wang et al., [@B211];

Welter-Stahl et al., [@B214];

Harhun et al., [@B82];

Yamamoto et al., [@B227];

Harrington et al., [@B83];

Wilson et al., [@B219];

Lewis et al., [@B130];

Cockayne et al., [@B39];

Cockayne et al., [@B38];

Compan et al., [@B46];

Serrano et al., [@B180];

Xiang et al., [@B225],

Calvert and Evans, [@B34];

Vlaskovska et al., [@B210];

Zhong et al., [@B237];

Zhong et al., [@B236];

Da Silva et al., [@B52];

Resende et al., [@B163];

Resende et al., [@B162];

Yuahasi et al., [@B234];

Schwindt et al., [@B179];

Franke et al., [@B71];

Kukley et al., [@B120];

Lalo et al., [@B121];

Yamamoto et al., [@B228];

Tsuda et al., [@B202];

Qureshi et al., [@B158],

Raouf et al., [@B160];

Ulmann et al., [@B204];

Toulme et al., [@B201];

Agresti et al., [@B3];

Matute et al., [@B140];

Worthington et al., [@B224];

Nori et al., [@B150];

Lewis and Evans, [@B128];

Lewis and Evans, [@B129];

Liang et al., [@B133];

Michel et al., [@B141];

Sun et al., [@B193];

Hickman et al., [@B88].

Heterooligomerization of P2XR subunits
======================================

In a systematic biochemical analysis of pairwise co-expressed Flag- and HA-tagged rat P2X subunits in HEK cells (Torres et al., [@B198]) it was found that (a) all subunits, except for P2X6 subunits, were able to homo-oligomerize (see also Aschrafi et al., [@B7]; Barrera et al., [@B12]), (b) P2X7 subunits did not hetero-oligomerize with other subunits (see also Nicke, [@B146]; Boumechache et al., [@B22]), and (c) the following pairs could be mutually co-purified: P2X1/2^\*^, P2X1/3, P2X1/5^\*^, P2X1/6, P2X2/3^\*^, P2X2/5^\*^, P2X2/6^\*^, P2X3/5, P2X4/5, P2X4/6^\*^, and P2X5/6. Heteromerization between P2X4 and P2X5 subunits was recently confirmed in an ELISA assay where a strong increase in the surface expression of a trafficking deficient P2X5 mutant by co-expression of the P2X4 subunit was observed (Compan et al., [@B46]). However, this heteromer has not been further characterized so far. In addition, P2X1/4^\*^ and P2X4/7^\*^ pairs were identified in co-purification studies (Nicke et al., [@B148]; Guo et al., [@B80]). Pairs marked with ^\*^ have also been functionally investigated and partly confirmed in additional studies that are described below. It has to be noted, however, that the differentiation of a heterotrimeric assembly between two given subunits or association of their respective homotrimeric complexes can generally not be achieved by standard co-purification protocols. In particular, in case of the P2X4/P2X7 interaction, data from more detailed biochemical analysis are in favor of the latter (Nicke, [@B146]; Antonio et al., [@B6]).

P2X1/2 heteromers
-----------------

### Biochemical evidence

Biochemical evidence for heteromeric P2X1/2Rs was further confirmed by studies in *Xenopus laevis* oocytes. In blue-native (BN)-PAGE and disulfide cross-linking studies, the metabolically labeled heterotrimeric P2X1/2R complexes were directly visualized and discriminated by their size from the respective homomers (Aschrafi et al., [@B7]; Marquez-Klaka et al., [@B139]). These data clearly excluded the possibility that the co-purification experiments were biased by artificial aggregation of the overexpressed protein or clustering of homotrimeric receptors (see below). Interestingly, no homotrimeric His-P2X1 complexes were detected in the BN-PAGE study and functional analysis of the receptors formed from substituted cysteine mutant P2X1 and P2X2 subunits revealed no current corresponding to homomeric P2X1Rs unless this subunit was injected in more than 6-fold excess. This suggests that in the presence of P2X2 subunits, the P2X1 subunit assembles preferentially as heteromer. However, discrepancies in the amount and speed in which the subunits are expressed could also account for this observation. Further analysis of the selectively radioiodinated heteromers in the plasma membrane revealed significantly more radioactivity in the band corresponding to the P2X~2~ subunit than in the His-tagged P2X~1~ subunit, suggesting a P2X1(2)~2~ stoichiometry (Aschrafi et al., [@B7]).

### Functional evidence

In a carefully conducted study by Brown et al. ([@B26]) the subtle differences between the fast desensitizing homomeric P2X1R and the heteromeric P2X1/2R could be discriminated by their sensitivity to extracellular pH. In contrast to P2X1 homomers, which show decreased agonist potency at acidic pH and are not affected by alkaline pH, agonist efficacy at the P2X1/2 heteromer is increased under both alkaline and acidic pH (Brown et al., [@B26]). In contrast to the biochemical studies, hetero-oligomerization was found to be inefficient in this study and only one in six oocytes showed the pH-potentiated P2X1-like responses. The difficulty to resolve the P2X1/2 heteromer current could be partly overcome by specific disulfide cross-linking of oocyte-expressed P2X1 and P2X2 mutants resulting in non-functional P2X1/2Rs and their activation following reduction with dithiothreitol (Marquez-Klaka et al., [@B139]). However, the reduced agonist sensitivity in these mutants has to be considered. The fast desensitizing phenotype found for the P2X1/2 heteromer is somehow exceptional because in all other functionally described P2X heteromers the slowly desensitizing subunit determines the kinetic of the heteromer.

### Evidence from native systems

The solid biochemical evidence for P2X1/2 heteromers is in contrast to the very limited evidence for this heteromer in native tissues. P2X1 and P2X2 subunits are widely distributed and overlap in many tissues (Burnstock and Knight, [@B32]). Transcripts of both subunits were found for example in vascular smooth muscle (Nori et al., [@B150]). However, generally, expression levels differed greatly, suggesting at most a small contribution of the respective heteromer. Whole-cell patch clamp and calcium imaging studies in mouse sympathetic neurons revealed a dominant P2X2-like phenotype and an αβ-meATP-sensitive receptor population that was largely absent in P2X1 knockout mice (Calvert and Evans, [@B34]). This αβ-meATP-sensitive current was blocked by Ca^2+^ and alkaline pH and it was concluded that it corresponds to a P2X1/2 heteromer. However, involvement of a third subunit was suggested since the current was not potentiated at acidic pH and showed a relatively slow time course of response.

P2X1/4 heteromers
-----------------

### Biochemical evidence

Biochemical evidence for heteromerization between co-expressed P2X1 and P2X4 subunits was excluded in two co-immunoprecipitation studies performed in HEK cells (Le et al., [@B124]; Torres et al., [@B198]), but was later found by co-purification and subsequent BN-PAGE analysis of *Xenopus* oocyte-expressed P2X1 and P2X4 subunits (Nicke et al., [@B148]).

### Functional evidence

Functional evidence for the formation of P2X1/4 heteromers came from the generation of a new phenotype upon co-expression of P2X1 and P2X4 subunits in *Xenopus* oocytes (Nicke et al., [@B148]). The proposed P2X1/4 heteromer shares the moderately desensitizing kinetics and fast recovery upon repeated activation with the P2X4R. In contrast to the P2X4 homomer and in common with the P2X1 homomer, however, it is activated by low micromolar concentrations of αβ-meATP and inhibited by suramin and TNP-ATP. Although these currents were reproducibly found upon co-expression of both subunits, they were comparably small, suggesting that previous attempts to detect this heteromer failed due to preferential homomerization of both subunits.

### Evidence from native systems

While heterologously expressed P2X4Rs are efficiently expressed as homotrimers in the plasma membrane, only few native receptors have been identified that resemble exactly the recombinant homomeric P2X4R, which is relatively insensitive to αβ-meATP (Coddou et al., [@B43]). A possible explanation is that both P2X4R expression and its cycling between intracellular compartments and the plasma membrane are highly dynamic and a predominant localization of P2X4Rs in intracellular compartments has been described (e.g., Bobanovic et al., [@B19]; Qureshi et al., [@B158]; Stokes and Surprenant, [@B191]; Toulme et al., [@B201]). Thus, P2X4Rs appear to be expressed and/or translocated to the plasma membrane only under specific conditions (e.g., upon activation of microglial cells) and might require additional subunits to be stabilized at the plasma membrane. Receptors incorporating P2X4 subunits have been postulated in a wide variety of tissues but little evidence for a P2X1/4 heteromer in native tissues has been provided so far. The P2X4 subunit has the widest distribution pattern of all P2X subunits and overlap with P2X1 subunits is found in many tissues. For example, P2X1 and P2X4 subunits have been identified in different types of immune cells (Sim et al., [@B182]; Wareham et al., [@B212]; Woehrle et al., [@B222]) and both subunits translocate to the immune synapse in stimulated T cells (Woehrle et al., [@B221]). However, data from knockout mice (Sim et al., [@B182]) and pharmacological analysis (Wareham et al., [@B212]) indicate the presence of homomeric rather than heteromeric P2X1 and P2X4Rs in mouse macrophages and human mast cells, respectively. Co-expression of both subunits was also found by single cell RT-PCR in smooth muscle cells of renal resistance arteries (Harhun et al., [@B82]). Here, the characteristics of a current component that was insensitive to the P2X1 antagonist NF279 (Rettinger et al., [@B165]) were consistent with the properties of the P2X1/4 heteromer. A role of a P2X1/4 heteromer was also considered in neurogenic contractions in the guinea pig urinary bladder (Kennedy et al., [@B107]) and not excluded in coronary artery smooth muscle (Conant et al., [@B47]) and erythrocytes (Skals et al., [@B183]).

P2X1/5 heteromers
-----------------

### Biochemical evidence

Biochemical evidence for the formation of heteromers consisting of P2X1 and P2X5 subunits was initially obtained from HEK293 cells transfected with epitope-tagged P2X1 and P2X5 subunits (Torres et al., [@B200]; Le et al., [@B125]). Here, the authors could demonstrate a direct association by co-purification. However, further biochemical evidence for P2X1 and P2X5 subunit interaction is still lacking in other *in vitro* models as well as in native tissues.

Several studies provide **functional evidence** for heteromerization of rat P2X1 and P2X5 subunits upon expression of both subunits in established expression systems like *Xenopus laevis* oocytes (Le et al., [@B125]; Rettinger et al., [@B164]) and cultured HEK293, CHO, and COS cells (Torres et al., [@B200]; Haines et al., [@B81]; Surprenant et al., [@B195]). The P2X1/5 heteromer shows distinct functional properties providing clear characteristics for its identification: (a) In contrast to the P2X1 homomer, its currents have a biphasic kinetic with a desensitizing peak and a non-desensitizing plateau current that are not desensitized by repeated agonist application. Depending on pH and ATP concentrations, the current response kinetics of the P2X1/5R differ (Surprenant et al., [@B195]). (b) It has a significant greater amplitude than the P2X5 homomer and, similar to the P2X1R, is activated by nanomolar ATP concentrations as well as by α,β-meATP (Torres et al., [@B200]; Haines et al., [@B81]; Le et al., [@B125]). (c) PPADS, suramin, and the specific P2X1R blocker NF449 antagonize with similar micromolar potencies the P2X1/5 heteromer and the P2X1 homomer (Haines et al., [@B81]; Rettinger et al., [@B164]), while the potency of TNP-ATP at the heteromer is markedly reduced in comparison to the P2X1 homomer and is more similar to that at the P2X5 homomer (Haines et al., [@B81]; Surprenant et al., [@B195]; Wildman et al., [@B217]). (d) A rebound current upon removal of agonist has been observed in some studies (Haines et al., [@B81]; Lalo et al., [@B121]). Peak currents of homomeric P2X5Rs are drastically decreased in a Ca^2+^ concentration dependent manner, whereas P2X1R responses are Ca^2+^ insensitive. Interestingly, increased extracellular Ca^2+^ significantly potentiated the steady-state currents of the P2X1/5 heteromer (Haines et al., [@B81]). Both acidification and alkalization have inhibitory effects on P2X1/5 heteromers while the homomeric receptors are only inhibited by an increased proton concentration (Surprenant et al., [@B195]).

### Evidence from native systems

In contrast to the widely distributed expression of the P2X1 subunit, P2X5 subunit RNA has only been detected in a restricted number of tissues including the heart, sensory and motor neurons of the cervical spinal cord (Collo et al., [@B44]), vascular smooth muscle (Phillips and Hill, [@B155]), and astrocytes (Lalo et al., [@B121]). The presence of P2X1/5 heteromers was suggested in guinea-pig submucosal arterioles where an increase in spontaneous excitatory junction potentials and higher current amplitudes were measured following repetitive ATP application and increased Ca^2+^ concentration, respectively (Surprenant et al., [@B195]). The electrophysiological profile of this smooth muscle tissue supports rather the presence of P2X1/5 heteromers than P2X1 homomers that has been described in HEK293 cells expressing P2X1 and P2X5 subunits. In more recent studies, based on quantitative real time PCR and pharmacological characterization by whole cell voltage clamp experiments, evidence for P2X1/5Rs in acutely isolated cortical astrocytes was obtained (Lalo et al., [@B121]). Here, the heteromer appears to be involved in astrocytic excitability, which is driven by phosphoinositides and mediated through the lipid-binding domain of the P2X1 subunit (Ase et al., [@B8]).

P2X2/3 heteromers
-----------------

The P2X2/3 heteromer was the first one to be identified functionally and biochemically (Lewis et al., [@B130]; Radford et al., [@B159]). So far, it represents the best characterized P2X heteromer and solid evidence for its *in vivo* expression in sensory neurons and its functional role in sensory neurotransmission exists. As several valuable reviews regarding their presence in sensory and autonomic neurons and their physiological importance are available (North, [@B151]; Brederson and Jarvis, [@B24]; Burnstock, [@B30]; Jarvis, [@B89]; Khakh and North, [@B110]), this chapter focuses only on some key findings and more recent studies.

### Biochemical evidence and stoichiometry

Evidence for heteromerization of P2X2 and P2X3 subunits was first obtained from co-immunoprecipitation studies of P2X2 and P2X3 subunits heterologously expressed in Sf9 insect cells (Radford et al., [@B159]). Subsequent co-precipitation studies by Torres et al. ([@B199]) confirmed the interaction of P2X2 and P2X3 subunits in HEK cells and more recently, BN-PAGE analysis of oocyte-expressed affinity-tagged hP2X2 and hP2X3 subunits demonstrated that both subunits co-assemble in trimeric P2X2/3Rs, which are efficiently expressed at the plasma-membrane (Hausmann et al., [@B85]). By analysis of disulfide bond formations between engineered cysteine residues in P2X2 and P2X3 subunits a "head-to-tail" subunit arrangement was originally demonstrated (Jiang et al., [@B93]). Furthermore, this study revealed the presence of adjacent P2X3 subunits but not P2X2 subunits, indicating a P2X2(3)~2~ stoichiometry of P2X2/3 channels. This stoichiometry was further confirmed by co-expression and functional analysis of P2X2 or P2X3 subunits containing single or double mutated ATP binding sites (Wilkinson et al., [@B218]). The P2X2(3)~2~ stoichiometry is indirectly supported by the finding that the degree of potentiation by extracellular Zn^2+^ in the P2X2/3 heteromer was comparable to the limited Zn^2+^ effect seen with concatenated P2X2 trimers that contained only one wild type subunit with two Zn^2+^ binding site mutants (Nagaya et al., [@B144]).

### Functional evidence

Functional evidence for the formation of P2X2/3 heteromers came initially from patch clamp analysis and comparison of rat nodose ganglia neurons and heterologously expressed P2X2 and P2X3 subunits (Lewis et al., [@B130]). This study revealed a non-desensitizing, αβ-meATP sensitive functional phenotype that could be unambiguously discriminated from the non-desensitizing α,β-meATP insensitive P2X2 and the fast desensitizing α,β-meATP sensitive P2X3 phenotypes. In addition, similar to the homomeric P2X2R, the heteromeric P2X2/3R is strongly potentiated at low pH values, while the homomeric P2X3R is much less pH sensitive and inhibited at low pH (King et al., [@B116]; Stoop et al., [@B192]; Wildman et al., [@B216]). For a more detailed analysis of the pharmacologic and kinetic properties of heterologously expressed P2X2/3Rs see (Stoop et al., [@B192]; Virginio et al., [@B209]; Burgard et al., [@B28]; Liu et al., [@B134]; Spelta et al., [@B188], [@B189]).

### Evidence from native systems

Evidence from native systems led initially to the identification of heteromeric P2X2/3Rs; α,βme-ATP-elicited current responses in nodose ganglia neurons did not match those of any singly expressed P2X subunit but were reproduced by co-expression of P2X2 and P2X3 subunits (Lewis et al., [@B130]). Subsequently, convincing evidence for the existence of heteromeric P2X2/3 channels was also provided in sympathetic, trigeminal, and dorsal root ganglia neurons (Cook et al., [@B48]; Thomas et al., [@B196]; Burgard et al., [@B29]; Grubb and Evans, [@B78]; Ueno et al., [@B203]; Dunn et al., [@B62], [@B63]; Lalo et al., [@B123]; Zhong et al., [@B237]; Petruska et al., [@B154]). Functional analysis of P2X2 and P2X2/P2X3 knockout mice further demonstrated/confirmed the presence of P2X2/3Rs in sensory and autonomic ganglia neurons and primary afferent nerve fibers in the urinary bladder (Cockayne et al., [@B38]) and defined the relative contribution of homomeric P2X2Rs and P2X3Rs and heteromeric P2X2/3Rs. This study revealed that ATP-induced currents in dorsal root ganglia (DRG) neurons are mediated by P2X3 and P2X2/3Rs, while those in nodose ganglion neurons are dominated by P2X2Rs and P2X2/3Rs. In sympathetic ganglion neurons, P2X3-containing receptors appear to be of minor functional importance and in the urinary bladder, P2X3Rs and P2X2/3Rs regulate urinary bladder reflexes. For more details about the role of these receptors in afferent sensory neurotransmission, mechanosensory transmission, and pain states see more recent reviews (Wirkner et al., [@B220]; Burnstock, [@B31]; Jarvis, [@B89]; Burnstock et al., [@B33]; Khakh and North, [@B110]). Interestingly, a recent study by Serrano and colleagues showed that in contrast to rodent DRGs, P2X2 transcripts are virtually absent in human and monkey DRG neurons (Serrano et al., [@B180]). Hence, primate DRG neurons seem to be devoid of P2X2/3Rs and ATP-induced responses are mediated exclusively by P2X3Rs. This finding may significantly affect the translatability of rodent data to validate these receptors as targets for the treatment of pain. P2X2 and P2X3 subunits are also co-expressed in sensory nerve fibers in taste buds (Bo et al., [@B17]) and gustatory nerves and P2X2/P2X3 double-knockout mice exhibited abolished responses to taste stimuli (Finger et al., [@B69]; Eddy et al., [@B64]).

P2X2/5 heteromers
-----------------

### Biochemical evidence

The rat P2X2/5 heteromer represents the most recent addition to the functionally characterized set of P2X subtypes. Apart from co-immunoprecipitation studies, biochemical evidence for its existence was provided by an ELISA assay that measured the increase in plasma membrane appearance of an HA-tagged trafficking-deficient P2X2 or P2X5 subunit by co-expression of the respective other subunit. In addition, their close spatial proximity was shown in bioluminescent resonance energy transfer studies and in bimolecular fluorescence complementation studies. In combination with cross-linking experiments using a membrane-impermeable cross-linker and native perfluorooctanoic acid (PFO)-PAGE analysis, these experiments indicated that P2X2/5 heterotrimers appear with both possible stoichiometries in the plasma membrane (Compan et al., [@B46]).

### Functional evidence

Functional evidence for this heteromer was obtained upon co-expression of both subunits in *Xenopus* oocytes and HEK cells (Compan et al., [@B46]). Although the presence of homomeric P2X2Rs could not be prevented, these studies revealed a novel phenotype in oocytes with slightly reduced sensitivity to ATP, ATPγS, and BzATP. Interestingly, BzATP showed strongly reduced efficacy at this heteromer. Inhibition of the supposed heteromer by TNP-ATP was increased while αβ-meATP was ineffective at concentrations of 300 μM. Co-expression of both subunits in oocytes and/or HEK cells also produced ATP-activated time-dependent permeability changes for NMDG, YO-PRO-1, and ethidium that showed a clearly different time course compared to homomeric P2X2Rs and higher absolute fluorescence values or even no saturation. Most remarkably, HEK cells co-expressing both subunits displayed plasma membrane blebbing and flipping of phosphatidylserine from the inside surface of the plasma membrane to the outside surface (PS flip), two hallmark properties of the P2X7R that were not seen in cells expressing P2X2 subunits alone.

### Evidence from native systems

Based on co-immunoprecipitation data from total brain and brain stem as well as immunohistochemistry data from dorsal root ganglia, spinal cord and trigeminal mesencephalic nucleus neurons in the mid pons, the presence of P2X2/5 heteromers in these tissues was suggested (Compan et al., [@B46]). However, the P2X2/5 heteromer differs from a previously characterized P2XR in trigeminal mesencephalic nucleus in its insensitivity to α,β-meATP (Patel et al., [@B153]).

P2X2/6 heteromers
-----------------

### Biochemical evidence and stoichiometry

Evidence for the interaction of P2X2 and P2X6 subunits was initially obtained by co-immunoprecipitation (Torres et al., [@B198]) and more recently, heterotrimerization of these subunits was confirmed by BN-PAGE analysis of oocyte expressed affinity-tagged hP2X2 and hP2X6 subunits (Hausmann et al., [@B85]). In contrast, to the heterotrimeric hP2X2/6 complex that is efficiently expressed at the plasma membrane, hP2X6 subunits do not form trimeric complexes (Aschrafi et al., [@B7]; Hausmann et al., [@B85]) and are retained in the ER. In HEK cells, co-expression of wt P2X6 subunits rescued ATP-elicited currents of P2X2 subunits harboring mutations in ATP-binding residues (such as K69A) that lead to the formation of non-functional homomeric P2X2Rs. Co-expression of wt P2X2 subunits with mutant P2X6 subunits and *vice versa* revealed that functional P2X2/6 heteromers consist of two P2X2 subunits and one P2X6 subunit. The P2X(2)~2~6 stoichiometry is in contrast to an AFM study of antibody-tagged isolated receptors, in which a variable subunit stoichiometry that depended on the relative subunit expression levels was observed (Barrera et al., [@B11]). However, in this study receptors purified from a crude membrane fraction, which also contained intracellular membranes, were analyzed.

### Functional evidence

Functional evidence for the existence of a P2X2/6 heteromer was initially shown in *Xenopus* oocytes (King et al., [@B114]). Expression of P2X6 subunits alone did not produce functional channels. Co-expression of both subunits resulted in ATP-induced currents that had fast activating and slowly desensitizing kinetics similar to homomeric P2X2Rs, but showed a biphasic current decay upon removal of ATP. In a subset of cells, an additional transient current component was present that was never seen in oocytes expressing exclusively the P2X2 subunit. Another remarkable difference is the loss of the agonist activity of Ap~4~A, which is a full agonist at the P2X2R, but was almost inactive at the P2X2/6 heteromer (King et al., [@B114]). In contrast to homomeric P2X2Rs, which exhibit a current amplitude potentiation at high proton concentrations, heteromeric P2X2/6Rs showed a decreased current amplitude at acidic pH. In HEK cells, however, the co-expression of a four-fold excess of the P2X6 subunit with the P2X2 subunit revealed a current that was potentiated at decreasing pH values and that was not seen in HEK cells expressing exclusively P2X2 subunits (Hausmann et al., [@B85]). Thus, the cellular background might influence these properties.

### Evidence from native systems

Co-expression of P2X2 and P2X6 transcripts has been described in some nuclei of the thalamus and hypothalamus and in specific laminae of the pineal gland (Collo et al., [@B44]). P2X2 and P2X6 subunits are also co-expressed in P19 embryonal carcinoma cells and neuronal stem cells (Resende et al., [@B162]; Schwindt et al., [@B179]). Ca^2+^-imaging-based pharmacological analysis revealed that P2X4Rs or P2X4-containing heteromultimers mediate ATP-induced calcium-responses of undifferentiated P19 embryonal carcinoma cells, while P2X2Rs and possibly heteromeric P2X2/6Rs are the major mediators of calcium-responses in neuronally differentiated cells after retinoic acid treatment (Resende et al., [@B162]). However, it remained partially unresolved whether the ATP-induced calcium transients of neuronally differentiated P19 cells are mediated by homomeric P2X2 or heteromeric P2X2/6Rs (Resende et al., [@B162]), although an simultaneous upregulation of the P2X2 and P2X6 expression was shown during neuronal differentiation (Resende et al., [@B163]). Also, during neuronal differentiation of neuronal progenitor cells of neurospheres the expression of P2X2 and P2X6 subunits was upregulated (Schwindt et al., [@B179]). In summary, although P2X2 and P2X6 are co-expressed in several tissues and their simultaneous regulation during neuronal differentiation was shown, there is to our knowledge no clear and direct evidence for the presence of functional heterotrimeric P2X2/6 assemblies in native cells or tissues.

P2X4/6 heteromers
-----------------

### Biochemical evidence

Biochemical evidence for the existence of P2X4/6 heteromers was initially demonstrated by co-purification of epitope-tagged P2X4 and P2X6 subunits upon expression in HEK293 cells (Le et al., [@B124]; Torres et al., [@B198]). There is a controversy regarding the ability of the P2X6 subtype to form homotrimers, since its expression in *in vitro* models failed to generate a functional receptor (Soto et al., [@B187]; Le et al., [@B124]; Khakh et al., [@B111]; Torres et al., [@B198]; King et al., [@B114]; Aschrafi et al., [@B7]). It has been suggested that the P2X6 subtype needs to get posttranslationally glycosylated to form a functional homomeric receptor in HEK293 cells (Jones et al., [@B99]). However, endogenous P2X4Rs have been reported in HEK293 cells (Worthington et al., [@B224]) (own unpublished observations) and could promote P2X6 subunit assembly and trafficking in form of heteromers. Using AFM in combination with surface biotinylation and immunofluorescence analysis, it has been shown that P2X6 subunits expressed in NRK cells do not form homotrimers. Substitution of 14 uncharged N-terminal amino acid residues by charged residues increased glycosylation and plasma membrane insertion of P2X6 subunits, indicating that their ER release is inhibited by this uncharged N-terminal region (Ormond et al., [@B152]). Co-immunoprecipitation and immunofluorescent studies in HEK293 cells showed a preferred assembly of P2X4 subunits into heterotrimeric P2X4/6Rs (Le et al., [@B124]; Bobanovic et al., [@B19]) and regulation of the P2X4/6 heteromer trafficking by the P2X4 subunit. The homomeric P2X4R showed an intracellular punctate distribution with sparse localization at the plasma membrane. In contrast, the GFP-tagged P2X6 subunit was diffusely distributed intracellularly and co-localized with the ER marker calreticulin, without any indication for the presence of the P2X6R at the cell surface. However, in the presence of the P2X4 subunit, the P2X6 subunit showed a similar punctate pattern as the homomeric P2X4R (Bobanovic et al., [@B19]).

### Functional evidence

The functional differentiation between homomeric P2X4 and heteromeric P2X4/6 assemblies is difficult, since the biophysical and pharmacological differences are not that clear and controverse data exist regarding the functional expression and αβ-meATP sensitivity of the P2X6R (Collo et al., [@B44]; Jones et al., [@B99]). The sensitivity of homomeric P2X4Rs to the partial agonist αβ-meATP is relatively low and species-dependent with EC~50~ values of 7 and 19.2 μM for mouse and human receptors, respectively, whereas rat P2X4Rs showed only very weak responses (Jones et al., [@B98]). Upon co-expression of P2X4 and P2X6 subunits in *Xenopus* oocytes, receptors were observed that showed (1) a three to five fold higher sensitivity to the partial agonists αβ-meATP and 2MeSATP than the P2X4R, (2) an enhanced inhibition by PPADS, suramin, and RB-2, and (3) peak current amplitudes that differed from those obtained by expression of the P2X4 subunit alone. However, current kinetics and current potentiation by IVM, as well as the effects of modulators like protons and zinc ions were undistinguishable between P2X4 homomers and P2X4/6 heteromers (Le et al., [@B124]; Khakh et al., [@B111]).

### Evidence from native systems

P2X4 and P2X6 RNAs are abundant and show a broad overlapping distribution throughout the central nervous system with significant amounts in the hippocampus and the cerebellum (Collo et al., [@B44]; Soto et al., [@B186],[@B187]). However, the function of homomeric P2X4 or heteromeric P2X4/6Rs in neurons remains unclear. Immunogold-labeling demonstrated the presence of P2X4 and P2X6 subunits in perikarya and dendritic spines of cerebellar Purkinje and hippocampal, pyramidal CA1 neurons, where they were suggested to form heteromeric assemblies (Rubio and Soto, [@B174]). Although P2X4 transcripts were found in hippocampal CA1 pyramidal neurons, αβ-meATP induced responses from most CA1 neurons remained unaltered upon IVM treatment, indicating that neither P2X4 homomers nor P2X4/6 heteromers are expressed in these cells (Khakh et al., [@B111]). However, a possible role of the P2X4 subunit in regulating synaptic plasticity was suggested based on studies with P2X4 knockout mice. The application of IVM on wt-mouse brain slices potentiated the EPSPs from CA1 neurons, whereas IVM had no effect in P2X4 knockout mice, which also showed an impaired long-term potentiation in the hippocampus (Sim et al., [@B181]). Early studies on rat hippocampal CA3 neurons revealed αβ-meATP-activated responses that were blocked by suramin, but were insensitive to PPADS (Ross et al., [@B173]), ruling out a contribution of P2X4Rs or P2X4/6Rs to neuronal excitation in these neurons. These findings were confirmed by later studies reporting that IVM had no effect on these cells (Mori et al., [@B143]; Kondratskaya et al., [@B118]). However, a significant contribution of P2X4 subunit-containing receptors to the generation of EPSPs was shown in neocortical neurons, where ATP- and αβ-meATP-mediated current responses were potentiated by IVM, but were not inhibited by PPADS (Lalo et al., [@B122]).

According to functional and biochemical analyses, P2X4 and P2X6 subunits are endogenously expressed in P19 murine embryonal carcinoma cells and show varying expression levels during the non-differentiated and neuronal progenitor states, suggesting a possible role for heteromeric P2X4/6Rs in regulation and induction of neurogenesis (Resende et al., [@B163], [@B162]). P2X4 and P2X6 subtype expression was also found in human non-cystic and cystic fibrosis epithelial cells. The knockdown of the P2X6 subunit by siRNA in these cells resulted in a significant attenuation of Zn^2+^-mediated Ca^2+^ influx, which was similar to the effect that occurred upon P2X4 subunit knockdown (Liang et al., [@B133]). Therefore, it was suggested that P2X4/6Rs play a role in the regulation of the Ca^2+^ influx that restores Cl^−^ secretion across the airway epithelia. Immunofluorescent stainings on human umbilicial endothelial cells revealed a colocalization of P2X4 and P2X6 subunits with VE-cadherin in cellular junctions, where they were suggested to be involved in the modulation of cell-cell adhesion processes via the mediation of Ca^2+^ signaling (Glass et al., [@B75]).

P2X4/7 heteromers
-----------------

P2X4R and P2X7R genes are located next to each other on human and rat chromosome 12 and murine chromosome 5. Both subunits share a high sequence similarity and show overlapping distribution in many tissues such as epithelia, endothelia, and immune cells.

### Biochemical evidence

Biochemical evidence for an association between P2X4 and P2X7 subunits was originally provided by co-immunoprecipitation from transfected HEK cells and from bone marrow-derived macrophages (Guo et al., [@B80]). Several subsequent studies, however, failed to confirm an association between both subunits within heterotrimeric complexes: BN-PAGE analysis of P2X7 complexes from various native tissues (bone marrow, lymph node, salivary gland) that contained both subunits revealed exclusively complexes that corresponded in size to the homomeric P2X7 complex, which can be differentiated by its size from any heteromeric P2X7-containing complex (Nicke, [@B146]). Likewise, BN-PAGE analysis and cross-linking data from primary cultures of rat macrophages and mouse microglia revealed an interaction between homomeric P2X7 and P2X4 complexes rather than P2X4/7 heteromers (Boumechache et al., [@B22]). This study further showed that P2X4Rs were predominantly intracellular, whereas P2X7Rs were mainly localized to the plasma membrane. However, both complexes could be co-immunoprecipitated. Co-expression of P2X4 and P2X7 subunits in NRK cells increased the surface expression of P2X4 subunits about two-fold (Guo et al., [@B80]). A pairing of P2X4 and P2X7 (and also P2X2 and P2X4) homotrimers was supported by cross-linking analysis and AFM imaging of HEK cell-expressed receptors (Antonio et al., [@B6]). In conclusion, there is currently no biochemical evidence for the presence of heterotrimeric P2X7Rs. It has to be noted, however, that P2X2 and P2X4 receptors have been found to be rather "sticky" proteins that appear to associate into higher aggregates more easily than other subunits (Aschrafi et al., [@B7]; Weinhold et al., [@B213]) (observation from the authors labs) and also P2X1 trimers appear to associate into dimers and higher complexes under certain conditions (Nicke, [@B146]). Whether this represents an expression-level and/or detergent-dependent artefact or is the result of a specific interaction is not clear at present. In the mouse alveolar epithelial E10 cell line, P2X4 and P2X7 receptors were shown to associate partly with lipid rafts and the P2X7R was found to interact with caveolin 1 (Barth et al., [@B13]). Co-immunoprecipitation, high resolution clear native PAGE, and BN-PAGE data suggest that all three proteins can be constituents of higher order protein complexes in these cells, but that caveolin 1 interacts only with P2X7Rs directly. In support of this, knock down by shRNAs demonstrated that downregulation of P2X7 subunits affects protein levels, localization, and complex organization of both caveolin 1 and P2X4. In contrast, P2X4 knock-down affected only P2X7 protein levels and localization but not caveolin 1 (Weinhold et al., [@B213]). In both cases, upregulation of the respective other P2X subunit was found. In the kidney, however, a mutual negative influence on subunit expression levels was found (Craigie et al., [@B51]). Using the respective knockout mice, it was shown that ablation of one subunit significantly reduced the mRNA levels of the respective other subunit.

### Functional evidence for mutual interactions

Functional evidence for mutual interactions between P2X4 and P2X7 subunits and/or receptors has been found in HEK cells co-transfected with both subunits (Guo et al., [@B80]; Casas-Pruneda et al., [@B35]). Thus, co-expression of a dominant negative P2X4 subunit was found to reduce the P2X7R currents without reducing their number in the plasma membrane and to confer IVM and TNP-ATP sensitivity as well as some BBG resistance to the P2X7R (Guo et al., [@B80]). In another study, the ATP-activated current decay in TEA^+^-containing solution was accelerated by co-expression of P2X4 subunits, which themselves showed no current under these ionic conditions. Furthermore, ethidium uptake was slowed down and decreased, a P2X fraction with lower ATP-sensitivity was observed, and a concentration-dependent lack of potentiation by IVM was seen in the presence of P2X4 subunits (Casas-Pruneda et al., [@B35]).

### Evidence from native systems

Co-expression of mouse P2X4 and P2X7 subunits in HEK cells reproduced the properties of ATP-activated currents in parotid acinar cells better than expression of each subunit alone (Casas-Pruneda et al., [@B35]). In freshly isolated rabbit airway ciliated cells an ATP-gated cation channel has been characterized (Ma et al., [@B136]) that shares the following properties with the P2X7R but not the P2X4R: (a) low sensitivity to ATP, (b) modulation by external Na^+^, (c) inhibition by extracellular divalent cations as well as (d) sensitivity to the P2X7 antagonists BBG and KN-62. However, in contrast to the P2X7R, this P2X(cilia) did not show pore dilation and, in agreement with P2X4R-associated properties, its current was augmented by Zn^2+^ and IVM. A mixture of both homomeric channels was excluded because the dose response curve of this channel could be described by a simple Hill equation and a P2X4/7R heteromer or a modified P2X4R were proposed as possible explanations. In support of a homomeric P2X7R, however, it was recently found that IVM also species-specifically potentiates P2X7R current amplitudes in a very similar manner as described for the P2X(cilia) (Casas-Pruneda et al., [@B35]; Nörenberg et al., [@B149]), see also Surprenant and North ([@B194]). Adding to the complexity of P2X7R characterization, polymorphisms have been identified in human and mouse P2X7 isoforms that influence their ability to form dye permeable pores, at least when studied in native cell preparations (Gu et al., [@B79]; Adriouch et al., [@B2]; Le Stunff et al., [@B127]; Sorge et al., [@B185]). It has to be noted, however, that no obvious functional differences were found if the respective recombinant channels were studied (Boldt et al., [@B21]; Donnelly-Roberts et al., [@B57]; Schwarz et al., [@B178]; Xu et al., [@B226]), suggesting the involvement of cell-specific factors in pore formation and/or assay-dependent/methodological differences in these studies. Thus, species-specific differences in pharmacology as well as polymorphisms need to be considered when characterizing P2X7Rs in native tissues.

Functional interactions between both receptors were recently also shown in mouse macrophage RAW246.7 cells, where P2X4 knock down by shRNA suppressed ATP-induced cell death and release of HMGB1 and Il1β, and facilitated the production of reactive oxygen species. However, P2X4 subunit knock down did not affect P2X7-mediated pore formation and MAPK signaling (Kawano et al., [@B102],[@B103]). From similar experiments, it was suggested that the P2X4R positively modulates P2X7-dependent cytokine release from bone marrow-derived dendritic cells (Sakaki et al., [@B176]). Most recently, a supposedly P2X4-containing receptor was described in murine myenteric neurons. Compared to the homomeric P2X4R this receptor had lower ATP sensitivity but increased sensitivity to the antagonists PPADS and suramin and its current was potentiated by IVM. Since P2X2 and P2X7 subunits had also been reported to be expressed in these cells, the possibility of P2X2/4/7 heteromers was considered (Maria et al., [@B137]).

Evidence for clustering of trimeric P2XRs
-----------------------------------------

For heterologously expressed P2X2Rs it was observed that properties such as mean open times, open channel noise, potentiation by Zn^2+^ and pH, the EC~50~ value for ATP, the ability to form large pores, and the inward rectification depend on the P2X2 expression level or density (Ding and Sachs, [@B56]; Clyne et al., [@B36]; Fujiwara and Kubo, [@B72]), suggesting interactions between homotrimeric P2X2Rs. A physical interaction between P2X2Rs is supported by biochemical evidence for an increased tendency of this receptor to form higher order complexes (Aschrafi et al., [@B7]) and high densities of GFP-tagged P2X2Rs could be observed upon their activation-dependent clustering in embryonic hippocampal neurons (Khakh et al., [@B112]). In addition, physical interactions between homotrimeric P2X7 and P2X4 receptors, and P2X2 and P2X4 receptors have been observed (Boumechache et al., [@B22]; Antonio et al., [@B6]). Whether these interactions are direct or via clustering molecules or within lipid domains and whether they have physiological relevance or represent overexpression artefacts remains to be determined. In this context, it is interesting that P2X4 and P2X7 were co-precipitated with the extracellular matrix component biglycan and soluble biglycan-induced clustering of P2X4 and P2X7 receptors with Toll-like receptor (TLR) 2/4 was found to underlie the activation of the inflammasome by this component (Babelova et al., [@B9]). Functional and physical interactions between P2XRs and other ion channels (e.g., members of the Cys-loop receptor and epithelial Na^+^ channel families) have also been described \[for a recent review see (Kaczmarek-Hajek et al., [@B100])\].

Summary and outlook
===================

P2XRs contain three intersubunit binding sites for orthosteric ligands. In heteromeric receptors all three binding sites differ significantly and thus offer theoretically the possibility for subtype-specific targeting of heteromers. However, proof of this concept is still lacking.

For heterologously expressed receptors, a combination of pharmacology and current kinetics in most cases allowed the discrimination of heteromeric receptor responses from those of homomeric receptors. However, identification of matching responses in native cells proved difficult and was only convincingly achieved in case of the P2X1/5 and P2X2/3 heteromers. Thus, it is likely that additional factors such as receptor modifications (e.g., phosphorylation), P2X splice variants, interacting proteins, P2XR clustering, the physiological expression background, expression levels, and trafficking influence P2XR properties under native conditions.

Co-immunoprecipitation still represents one of the standard experiments to proof a physical interaction between proteins. However, several pitfalls need to be considered: First, the method does not allow to differentiate between association of trimeric receptors and heterotrimerization of subunits. Second, it is difficult to exclude that the observed interaction is due to artificial aggregation of the overexpressed protein or occurs artificially during the solubilization and purification process, which is generally optimized toward the detection of an interaction. Third, if performed in native tissues, this method also critically depends on the availability of reliable antibodies. Thus, methods for the direct visualization of complexes and biochemical and/or functional assays, which are able to detect interactions within the membrane, are needed and experiments should preferably be performed on native preparations or at physiological expression levels. With RNA knockdown technology, knockout animals, and transgenic animals expressing tagged P2XRs, suitable control experiments can be performed and in combination with the increasingly available subtype selective compounds, knockout animals provide valuable models to decipher the composition of heteromeric complexes by pharmacological means.
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